The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Molecular adsorbent recirculating system for acute and acute-on-chronic liver failure: A meta-analysis
Open accessAbstract
Molecular adsorbent recirculating system (MARS) is an important option for patients with liver failure to give them additional time for recovery or to serve as a “bridge” to transplantation. However, its effect on survival for such patients is not well known. Our aim was to assess the treatment effects of MARS on patients with acute and acute-on-chronic liver failure. The outcomes measure evaluated was survival. We searched Medline (1966-2002) and EMBASE (1974-2002) using the terms liver failure, liver support systems, and MARS. Our search was extended to the Cochrane Controlled Trials Registry Database, published abstracts from 5 international conferences, Teraklin (the manufacturer of MARS), known contacts, and bibliographies from each full-published report. We included trials published in English and non-English languages. Eligible studies were randomized and nonrandomized controlled trials, which compared the treatment effects of MARS with standard medical treatment. Of the 206 articles screened, 4 randomized controlled trials including 67 patients were analyzed. Two nonrandomized trials with 61 patients were used for explorative analysis. The methodology, population, intervention, and outcomes of each selected trial were evaluated by duplicate independent review. Disagreements were resolved by consensus. In the primary meta-analysis, MARS treatment did not appear to reduce mortality significantly compared with standard medical treatment [relative risk (RR), 0.56; 95% confidence interval (CI), 0.28-1.14; P = .11]. Only 1 of the 4 randomized trials analyzed showed significant reduction in mortality. Sensitivity analysis of 3 peer-reviewed trials did not reduce mortality significantly with MARS treatment (RR, 0.72; 95% CI, 0.37-1.40; P = .33). Subgroup analysis of 2 trials for acute liver failure and another 2 trails for acute-on-chronic liver failure also did not reveal any benefit to survival with MARS treatment. In contrast, explorative analysis of 2 nonrandomized trials showed a significant survival benefit with MARS treatment (RR, 0.36; 95% CI, 0.17-0.76; P = .007). This was possibly related to bias in the selection of patients in the nonrandomized trials. In conclusion, MARS treatment had no significant survival benefit on patients with liver failure when compared with standard medical therapy. However, we found only a few trials with a small number of patients for the analysis, allowing for the possibility of false negative and erroneous conclusions. Well-conducted randomized trials are strongly recommended to define the role of MARS in the treatment of patients with liver failure. (Liver Transpl 2004;10:1099-1106.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moher, D., Cook, D. J., Eastwood, S., Olkin, I., Rennie, D., & Stroup, D. F. (1999) · The Lancet · doi:10.1016/s0140-6736(99)04149-5 · Cited by 4,826
Publication bias in clinical research
Easterbrook, P. J., Gopalan, R., Berlin, J. A., & Matthews, D. R. (1991) · The Lancet · doi:10.1016/0140-6736(91)90201-y · Cited by 3,109
The Hazards of Scoring the Quality of Clinical Trials for Meta-analysis
Jüni, P. (1999) · JAMA · doi:10.1001/jama.282.11.1054 · Cited by 1,981
Randomisation to protect against selection bias in healthcare trials
Odgaard-Jensen, J., Vist, G. E., Timmer, A., Kunz, R., Akl, E. A., Schünemann, H., Briel, M., Nordmann, A. J., Pregno, S., & Oxman, A. D. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000012.pub3 · Cited by 439
Cited by
Sarin, S. K., Kedarisetty, C. K., Abbas, Z., Amarapurkar, D., Bihari, C., Chan, A. C. Y., Chawla, Y. K., Dokmeci, A. K., Garg, H., Ghazinyan, H., et al. (2014) · Hepatology International · doi:10.1007/s12072-014-9580-2 · Cited by 1,481
Sarin, S. K., Kumar, A., Almeida, J. A., Chawla, Y. K., Fan, S. T., Garg, H., de Silva, H. J., Hamid, S. S., Jalan, R., Komolmit, P., et al. (2009) · Hepatology International · doi:10.1007/s12072-008-9106-x · Cited by 763
Bacterial Infections, Sepsis, and Multiorgan Failure in Cirrhosis
Tandon, P., & Garcia-Tsao, G. (2008) · Seminars in Liver Disease · doi:10.1055/s-2008-1040319 · Cited by 551
Lee, W. M., Stravitz, T. R., & Larson, A. M. (2012) · Hepatology · doi:10.1002/hep.25551 · Cited by 550
Acute-on-chronic liver failure: A new syndrome that will re-classify cirrhosis
Arroyo, V., Moreau, R., Jalan, R., & Ginès, P. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.11.045 · Cited by 451
Hassanein, T. I., Tofteng, F., Brown, R. S., McGuire, B., Lynch, P., Mehta, R., Larsen, F. S., Gornbein, J., Stange, J., & Blei, A. T. (2007) · Hepatology · doi:10.1002/hep.21930 · Cited by 407
Garg, V., Garg, H., Khan, A., Trehanpati, N., Kumar, A., Sharma, B. C., Sakhuja, P., & Sarin, S. K. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.11.027 · Cited by 391
Metadata
- Authors
- Khuroo, M. S., Khuroo, M. S., & Farahat, K. L. C.
- Venue
- Liver Transplantation
- Published
- 2004-09
- Volume
- 10
- Issue
- 9
- Pages
- 1099-1106
- ISSN
- 1527-6465 (ISSN-L)
- OpenAlex
- W2046817661
- Cited by
- 176
- References
- 4
- FWCI
- 1.73
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.